Whatever you think of Donald Trump’s tariff policies, one fact stands out: companies are looking to invest more in the United States. They want to avoid the negative impacts of tariffs on their business.

Eli Lilly wants the most optimal locations to host its new manufacturing facilities in the U.S.—and it’s open to pitche | Eli Lilly has established an online portal to accept submissions for possible locations of future U.

Eli Lilly and Co. said Wednesday it will open four new U.S. manufacturing "mega sites" in the next five years, in a bid to reduce its reliance on overseas suppliers and take more control over its supply chain.

Pharmaceutical giant expects the move will create 3,000 high-skilled jobs and provide work for approximately 10,000 construction workers.

NovoCare Pharmacy will provide all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients without insurance.

Eli Lilly also responded to the President's tariff warnings by investing $27 billion to construct four manufacturing facilities across the U.S. in five years.

Novo Nordisk's NovoCare will now provide uninsured or underinsured patients access to Wegovy for just $499 per month—less than half of its list price.

Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the United States and make the nation the world's leader in pharmaceutical production.

Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional $27 billion to build four new manufacturing plants in the United States, shoring up domestic manufacturing as President Donald Trump threatens new tariffs on pharmaceuticals.

Eli Lilly said it plans to build three new plants in the United States to make the key ingredients used in pharmaceuticals, part of a doubling of its investment in manufacturing.